The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...
The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.
H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...
HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.
Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...